Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Change in Accured Expenses (2023 - 2026)

Cannabis Bioscience International Holdings filings provide 4 years of Change in Accured Expenses readings, the most recent being -$25993.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 274.71% to -$25993.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $39699.0, a 151.87% increase, with the full-year FY2025 number at -$65515.0, down 177.27% from a year prior.
  • Change in Accured Expenses reached -$25993.0 in Q1 2026 per CBIH's latest filing, down from $116116.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $116116.0 in Q4 2025, with the low at -$61439.0 in Q2 2024.
  • A 4-year average of $14258.2 and a median of $23023.0 in 2023 define the central range for Change in Accured Expenses.
  • Year-over-year, Change in Accured Expenses tumbled 351.59% in 2024 and then surged 487.45% in 2025.
  • Year by year, Change in Accured Expenses stood at $43566.0 in 2023, then tumbled by 168.79% to -$29969.0 in 2024, then surged by 487.45% to $116116.0 in 2025, then tumbled by 122.39% to -$25993.0 in 2026.
  • Per Business Quant, the three most recent readings for CBIH's Change in Accured Expenses are -$25993.0 (Q1 2026), $116116.0 (Q4 2025), and -$50424.0 (Q2 2025).